Xeris Biopharma Holdings, Inc.
XERSHealthcareNASDAQDrug Manufacturers - Specialty & Generic · Last scanned Oct 26, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Xeris Biopharma Holdings, Inc. focuses on Drug Manufacturers - Specialty & Generic services and products. Xeris Biopharma Holdings, Inc., a commercial-stage biopharmaceutical company, engages in developing and commercializing therapies for chronic endocrine and neurological diseases in Illinois. At a $1.86B market cap, Xeris Biopharma Holdings, Inc. ranks as a small-cap company within healthcare. It offers Gvoke, a ready-to-use liquid-stable glucagon for the treatment of severe hypoglycemia in pediatric and adult patients; Keveyis, a therapy for the treatment of hyperkalemic, hypokalemic, and related variants of primary periodic paralysis; and Recorlev, a cortisol synthesis inhibitor for the treatment of endogenous hypercortisolemia in adult patients with Cushing's syndrome.
Market Cap
$1.86B
Beta
0.84
P/E (TTM)
—
P/E (Fwd)
51.86
EPS (TTM)
$-0.10
EPS (Fwd)
$0.20
ROE
—
ROA
6.1%
Cash
$121.7M
Total Debt
$289.4M
Free CF
$52.5M
52W Change
9.6%
Annual Financials
Cash vs Debt
Where XERS stands vs its 150-day and 200-day moving averages
As of the October 13, 2026 close, XERS finished 41.93% above its 150-day moving average ($7.37) and 43.48% above its 200-day moving average ($7.29). This snapshot is end-of-day data shown with a five-trading-day delay on the free plan; Premium members see readings from the latest close.
Is XERS overbought or oversold?
At the October 13, 2026 close, XERS's RSI(14) was 72.6, in overbought territory (above 70). The MACD histogram was positive, so short-term momentum leaned bullish at that close. These readings are historical, refresh daily after market close, and are not investment advice.
On the balance sheet, XERS has $121.7M in cash with $289.4M in obligations. The ability to service this debt comfortably depends on continued operational cash generation. Annual free cash flow of $52.5M supports ongoing capital allocation decisions and provides a cushion against unexpected expenses or downturns. An ROA of 6.1% suggests reasonable efficiency in deploying the company's asset base. Revenue has grown from $110.2M (2022) to $291.8M (2025), reflecting a 165% increase over the period.
Investors considering Xeris Biopharma Holdings, Inc. should weigh the typical risks associated with XERS's sector, size, and financial profile against their own risk tolerance and investment objectives. These risk factors are not exhaustive — macroeconomic shifts, regulatory changes, and competitive dynamics can all influence Xeris Biopharma Holdings, Inc.'s trajectory.